When adjusted for respiratory disease, endocrine disease, obesity, diabetes, and circulatory and neurological diseases, the odds were 1.3, 2.2, 1.48, 2.33, 2.85, and 2.6, respectively. The prevalence of the varicella zoster virus in COVID-19 patients was 1.8% compared to 0.43% in the hospital population, odds ratio of 5.26 before adjustment, and 5.2, 5.47, and 4.76 after adjusting for gender, age, and race, respectively. After adjustment for respiratory disease, endocrine disease, obesity, diabetes, circulatory disease, and smoking, the odds were 1.94, 3.18, 1.37, 3.54, 3.7, and 5.1, respectively. Of those 414 cutaneous reactions, shingles was seen in 1 of 34 receiving first Pfizer vaccine (2.9 of cutaneous reactions) and 4 of 40. al, (1) reviewed a registry of 414 subjects that had cutaneous reactions following mRNA COVID vaccines. When adjusted for gender, race, and age, the odds were 5.18, 4.48, and 4.61, respectively. These represent infrequent occurrences, and it has not been confirmed to be a causal link. The prevalence of the herpes simplex-1 occurrence in the COVID-19 group was 2.81% compared to 0.77% in the hospital population odds ratio of 5.27. The University of Florida patient registry i2b2 with ICD-10 diagnosis codes was used for retrieval of patients with diagnosis of COVID-19 and each of the other viruses over the period of October 2015-June 2020. However, since most of these were case reports, it is impossible to assess the prevalence of these associations. Several reports associated this human herpes virus with COVID-19 infection and have claimed that it can be an indicator for latent COVID-19 infection. Reactivation of herpes family viruses in immunocompromised patients may result in detrimental outcomes for the hosts therefore, herpes simplex virus-1 and varicella zoster virus infections in the context of COVID-19 may have clinical and prognostic implications.

Herpes linked to covid vaccine